Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
HALO 
Halozyme Therapeutics Inc (HALO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: HALO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Year Target Price $67
Year Target Price $67
| 2 | Strong Buy |
| 2 | Buy |
| 3 | Hold |
| 0 | Under performing |
| 1 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -28.66% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.43B USD | Price to earnings Ratio 13.89 | 1Y Target Price 67 |
Price to earnings Ratio 13.89 | 1Y Target Price 67 | ||
Volume (30-day avg) 8 | Beta 1.19 | 52 Weeks Range 42.01 - 70.51 | Updated Date 06/29/2025 |
52 Weeks Range 42.01 - 70.51 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.76 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 44.76% | Operating Margin (TTM) 53.44% |
Management Effectiveness
Return on Assets (TTM) 18.5% | Return on Equity (TTM) 147.06% |
Valuation
Trailing PE 13.89 | Forward PE 11 | Enterprise Value 7195357830 | Price to Sales(TTM) 5.93 |
Enterprise Value 7195357830 | Price to Sales(TTM) 5.93 | ||
Enterprise Value to Revenue 6.64 | Enterprise Value to EBITDA 10.21 | Shares Outstanding 123221000 | Shares Floating 121828603 |
Shares Outstanding 123221000 | Shares Floating 121828603 | ||
Percent Insiders 1.18 | Percent Institutions 101.98 |
Analyst Ratings
Rating 3 | Target Price 67 | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold 3 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Halozyme Therapeutics Inc
Company Overview
History and Background
Halozyme Therapeutics, Inc. was founded in 1998. Initially focused on recombinant human hyaluronidase enzyme (rHuPH20), it has evolved into a biopharma company focused on drug delivery and novel oncology therapeutics. Key milestones include the development of ENHANZE drug delivery technology and strategic partnerships with major pharmaceutical companies.
Core Business Areas
- ENHANZE Drug Delivery Technology: This platform enables subcutaneous delivery of injectable biologics, often replacing intravenous infusions. Halozyme receives royalties and milestone payments from partners using ENHANZE.
- Oncology Therapeutics: Halozyme has developed a portfolio of oncology assets, including PEGPH20. This molecule has not demonstrated clinical success and is no longer a key business line.
Leadership and Structure
Halozyme is led by Helen Torley (President and CEO). The organizational structure includes departments focused on research and development, commercial operations, finance, and legal/compliance.
Top Products and Market Share
Key Offerings
- ENHANZE Technology: ENHANZE is Halozyme's primary revenue driver. It allows for subcutaneous delivery of biologics. Specific market share data for ENHANZE itself is not publicly available; its value is derived from the partnered drugs that utilize the technology. Competitors include companies with alternative drug delivery platforms and those developing their own subcutaneous formulations. Partners include Roche (RHHBY), Johnson & Johnson (JNJ), Bristol Myers Squibb (BMY).
Market Dynamics
Industry Overview
The drug delivery technology market is experiencing growth driven by the increasing demand for convenient and patient-friendly drug administration methods, particularly for biologics. There is increasing interest in oncology and innovative drug delivery technologies.
Positioning
Halozyme is a leader in subcutaneous drug delivery through its ENHANZE platform. Its competitive advantage lies in the proven effectiveness and broad applicability of its technology, supported by established partnerships with major pharmaceutical companies.
Total Addressable Market (TAM)
The TAM for subcutaneous drug delivery is substantial and growing, estimated at billions of dollars annually. Halozyme's positioning is strong due to its established partnerships and proven technology, allowing it to capture a significant portion of this market.
Upturn SWOT Analysis
Strengths
- Proprietary ENHANZE drug delivery technology
- Established partnerships with major pharmaceutical companies
- Recurring revenue stream from royalties and milestones
- Strong financial position
Weaknesses
- Dependence on partners for commercial success of ENHANZE-enabled drugs
- Limited control over the development and marketing of partnered drugs
- Potential for competition from alternative drug delivery technologies
Opportunities
- Expansion of ENHANZE to new therapeutic areas and biologics
- Potential for new partnerships with additional pharmaceutical companies
- Development of novel oncology therapeutics
Threats
- Failure of partnered drugs in clinical trials
- Loss of exclusivity for ENHANZE technology
- Competition from alternative drug delivery technologies
- Changes in regulatory landscape
Competitors and Market Share
Key Competitors
- RHHBY
- JNJ
- BMY
- LLY
Competitive Landscape
Halozyme's ENHANZE platform holds a significant position in the subcutaneous drug delivery market. Its strength lies in established partnerships, but it faces competition from other drug delivery methods. The company must continue to innovate and expand its partnerships to maintain its competitive edge.
Major Acquisitions
Antares Pharma
- Year: 2022
- Acquisition Price (USD millions): 960
- Strategic Rationale: Expand Halozyme's portfolio with Antares' auto-injector technology and commercial products. To further enhance drug delivery capabilities and revenue streams.
Growth Trajectory and Initiatives
Historical Growth: Halozyme's growth has been driven by the increasing adoption of ENHANZE by its partners and the achievement of milestones related to partnered drug development.
Future Projections: Analyst estimates suggest continued revenue growth driven by ENHANZE royalties and milestone payments.
Recent Initiatives: Recent initiatives include signing new partnership agreements and focusing on life-cycle management for ENHANZE.
Summary
Halozyme Therapeutics is a biopharma company with a strong position in subcutaneous drug delivery through its ENHANZE technology. Partnerships drive revenue. The company is vulnerable to clinical trial failures of its partners' products and faces competition from alternative drug delivery technologies. Recent acquisitions should help diversify and strengthen their product offerings.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Halozyme Therapeutics Inc. Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share data may be estimates and subject to change. Future performance is not guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Halozyme Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2004-03-16 | President, CEO & Director Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 350 | Website https://halozyme.com |
Full time employees 350 | Website https://halozyme.com | ||
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company offers Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; HYQVIA to treat primary immunodeficiency disorders; Ocrevus (ocrelizumab) for multiple sclerosis; N6LS and cabotegravir to treat HIV; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; Epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat solid tumors; teriparatide injections; OTREXUP, an SC methotrexate injection for severe active rheumatoid arthritis, severe recalcitrant psoriasis, and active polyarticular juvenile idiopathic arthritis; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. The company has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; and Acumen Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.